Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04691115
Other study ID # 1476-291-001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date December 16, 2020
Est. completion date January 26, 2022

Study information

Verified date May 2023
Source AnaMar AB
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a First in Human (FIH), double-blind, randomised, placebo-controlled study designed to evaluate safety, tolerability and PK of single and multiple ascending oral doses of AM1476 in healthy subjects.


Description:

Part A (SAD); In the SAD part of the study, single oral doses of AM1476 will be administered in up to 9 sequential groups, each consisting of 8 subjects randomised to recieve either AM1476 or placebo in a 3:1 ratio. The first 2 subjects in each group will be dosed in a sentinel fashion, 1 subject will receive AM1476 and the other will receive placebo as randomised. The SAD part incorporating a 2-period crossover arm for a food-effect evaluation in 2 groups. Part B (MAD); The MAD part of the study will explore multiple ascending dosing of AM1476 for 10 days. AM1476 will be administered in up to 6 sequential groups, each consisting of 8 subjects randomised to recieve either AM1476 or placebo in a 3:1 ratio.


Recruitment information / eligibility

Status Completed
Enrollment 97
Est. completion date January 26, 2022
Est. primary completion date January 26, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Males or females, of any race, between 18 and 60 years of age, inclusive. 2. A body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive. 3. In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations (congenital non-haemolytic hyperbilirubinemia [eg, suspicion of Gilbert's syndrome based on total and direct bilirubin] is not acceptable) at Screening and/or Check-in (Day -1) as assessed by the Investigator (or designee). 4. Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception as detailed in Appendix 4. 5. Able to comprehend and willing to sign an ICF and to abide by the study restrictions. Exclusion Criteria 1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee). 2. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee). 3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed). 4. Any of the following observed in at least 2 of 3 ECG measurements performed: 1. QTcF > 450 msec. 2. QRS duration > 110 msec. 3. PR interval > 220 msec. 4. findings which would make QTc measurements difficult or QTc data uninterpretable. 5. Any history of additional risk factors for torsades de pointes (eg, heart failure, hypokalaemia, family history of long QT syndrome). 6. Any history or current controlled or uncontrolled hypertension or systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg confirmed by repeat measurement. 7. History of alcoholism or drug/chemical abuse within 2 years prior to Check-in (Day -1). 8. Alcohol consumption of > 21 units per week for males and > 14 units per week for females. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits. 9. Positive alcohol breath test result or positive urine drug screen (confirmed by repeat) at Screening or Check-in (Day -1). 10. Positive hepatitis panel and/or positive human immunodeficiency virus test (Appendix 2). 11. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days prior to dosing. 12. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's Wort, within 30 days prior to dosing, unless deemed acceptable by the Investigator (or designee). 13. Use or intend to use any prescription medications/products other than hormone replacement therapy, oral, implantable, transdermal, injectable, or intrauterine contraceptives within 14 days prior to dosing, unless deemed acceptable by the Investigator (or designee). 14. Use or intend to use slow release medications/products considered to still be active within 14 days prior to Check-in (Day -1), unless deemed acceptable by the Investigator (or designee). 15. Use or intend to use any non-prescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 7 days prior to Check-in (Day -1), unless deemed acceptable by the Investigator (or designee). 16. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in (Day -1) or positive cotinine at Screening or Check-in (Day -1). 17. Ingestion of poppy seeds, Seville orange, or grapefruit-containing foods or beverages within 7 days prior to Check-in (Day -1). 18. Subjects who are vegetarians, vegans, or are unable to consume the high-fat breakfast (subjects who will participate in a food-effect evaluation [planned to be Group A3] only). 19. Receipt of blood products within 2 months prior to Check-in (Day -1). 20. Donation of blood from 3 months prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening. 21. Poor peripheral venous access. 22. Have previously completed or withdrawn from this study or any other study investigating AM1476, and have previously received AM1476. 23. Subjects who are not willing to minimise or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) following administration of study drug until 2 weeks after the last dose. 24. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AM1476
AM1476 Capsules
Placebo
Placebo Capsules

Locations

Country Name City State
United Kingdom Covance Clinical Research Unit Leeds

Sponsors (2)

Lead Sponsor Collaborator
AnaMar AB Covance

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Treatment-Emergent Adverse Events, including abnormal laboratory events Frequency, severity and seriousness of adverse events (AEs) including physical examination, safety laboratory parameters, vitals signs, body temperature and ECGs will be analyzed. Through study completion, an average of 7 weeks
Secondary Cmax maximum plasma concentration SAD: From pre-dose to up to 48 hours post-dose; MAD: From pre-dose to 24 hours post first dose and 48 hours post last dose
Secondary Tmax time to Cmax SAD: From pre-dose to up to 48 hours post-dose; MAD: From pre-dose to 24 hours post first dose and 48 hours post last dose
Secondary terminal half-life SAD: From pre-dose to up to 48 hours post-dose; MAD: From pre-dose to 24 hours post first dose and 48 hours post last dose
Secondary AUC0-t area under the curve from time 0 to time t SAD: From pre-dose to up to 48 hours post-dose; MAD: From pre-dose to 12/24 hours post first dose and 48 hours post last dose
Secondary CL/F apparent total clearance SAD: From pre-dose to up to 48 hours post-dose; MAD: From pre-dose to 12/24 hours post first dose and 48 hours post last dose
Secondary Vz/F apparent volume of distribution during the terminal phase SAD: From pre-dose to up to 48 hours post-dose; MAD: From pre-dose to 12/24 hours post first dose and 48 hours post last dose
See also
  Status Clinical Trial Phase
Recruiting NCT05073744 - Nalbuphine Versus Morphine for Perioperative Tumor Ablation Phase 4
Completed NCT03969641 - Safety of RIV4 Versus IIV4 in Pregnant Women Phase 4
Completed NCT05592951 - Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers N/A
Completed NCT04693429 - Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ Phase 1
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01243502 - A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers Phase 1
Completed NCT06072170 - Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience Phase 1
Completed NCT05076253 - Efficacy of Ivermectin in COVID-19 Phase 1/Phase 2
Recruiting NCT06060379 - Giochiamo 626 - Gaming for Health and Safety in Workplaces N/A
Recruiting NCT05298800 - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Phase 4
Completed NCT05188638 - Safety of Ascending Single and Multiple Doses of Nebulised SoftOx Inhalation Solution in Healthy Subjects Phase 1
Completed NCT05145621 - Oral Bio-equivalence Study Phase 1
Recruiting NCT05580159 - New Generation mRNA Booster Vaccine Against Emerging VOCs Phase 3
Not yet recruiting NCT04596956 - Safety and Efficacy of Sodium Bicarbonate Ringer Injection Phase 4
Completed NCT03033329 - Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4 Phase 1
Terminated NCT01929811 - NeoMET Study in Neoadjuvant Treatment of Breast Cancer Phase 2
Completed NCT01193335 - Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants. Phase 4
Completed NCT03300466 - A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds N/A
Active, not recruiting NCT05686161 - mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs Phase 3